If the hypothesis that CD103-expressing TILs exert stronger antitumor activity in the corresponding tumor regions is correct, it is conceivable that regions with no or low presence of CD103+ cells gain a relative growth advantage and immune-evasive selection benefit. This evidence concerns the gene ITGAE and neoplasm.